ArticleJournal of virology2022
Evaluation of the Deletion of MGF110-5L-6L on Swine Virulence from the Pandemic Strain of African Swine Fever Virus and Use as a DIVA Marker in Vaccine Candidate ASFV-G-ΔI177L.
Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 40 citations in OpenAlex.
- MGF110-2L deletion prevents IFN-I and inflammatory response, resulting in partial attenuation and protection against virulent ASFV.Journal of virology · 2026Article
- Characterization of African swine fever outbreaks in Hong Kong SAR, winter 2023 to 2024.Microbiology spectrum · 2026Article
- The Prospects and Challenges of Live Attenuated Vaccines Against African Swine Fever Virus in Vietnam.Vaccines · 2026Review
- Live Attenuated Vaccines for African Swine Fever: Perspectives on Their Use and Strategic Directions.Transboundary and emerging diseases · 2026Review
- Article
- Hope and hurdles: unlocking the potential of modified live virus vaccines for African swine fever.Emerging microbes & infections · 2025Review
- Temporal Dynamics of Cytokine, Leukocyte, and Whole Blood Transcriptome Profiles of Pigs Infected with African Swine Fever Virus.Pathogens (Basel, Switzerland) · 2025Article
- Review
- Advances in African swine fever virus molecular biology and host interactions contributing to new tools for control.Journal of virology · 2025Review
- Deletion of B125R increases protection induced by a genotype II African swine fever vaccine candidate.NPJ vaccines · 2025Article
- Article
- Article
- Challenges for Animal Health and Production in the Tropics and Mediterranean for the next 55 years.Tropical animal health and production · 2024Article
- Generation and Genetic Stability of a PolX and 5' MGF-Deficient African Swine Fever Virus Mutant for Vaccine Development.Vaccines · 2024Article
- Recent progress on gene-deleted live-attenuated African swine fever virus vaccines.NPJ vaccines · 2024Review
- Article
- A Deep Sequencing Strategy for Investigation of Virus Variants within African Swine Fever Virus-Infected Pigs.Pathogens (Basel, Switzerland) · 2024Article
- African swine fever at the wildlife-livestock interface: challenges for management and outbreak response within invasive wild pigs in the United States.Frontiers in veterinary science · 2024Review
- A quadruple fluorescence quantitative PCR method for the identification of wild strains of african swine fever and gene-deficient strains.Virology journal · 2023Article
- Involvement of the MGF 110-11L Gene in the African Swine Fever Replication and Virulence.Vaccines · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
African swine fever virus (ASFV) is responsible for an ongoing pandemic that is affecting central Europe, Asia, and recently the Dominican Republic, the first report of the disease in the Western Hemisphere in over 40 years. ASFV is a large, complex virus with a double-stranded DNA (dsDNA) genome that carries more than 150 genes, most of which have not been studied. Here, we assessed the role of the MGF110-5L-6L gene during virus replication in cell cultures and experimental infection in swine. A recombinant virus with MGF110-5L-6L deleted (ASFV-G-ΔMGF110-5L-6L) was developed using the highly virulent ASFV Georgia (ASFV-G) isolate as a template. ASFV-G-ΔMGF110-5L-6L replicates in swine macrophage cultures as efficiently as the parental virus ASFV-G, indicating that the MGF110-5L-6L gene is nonessential for virus replication. Similarly, domestic pigs inoculated with ASFV-G-ΔMGF110-5L-6L presented with a clinical disease undistinguishable from that caused by the parental ASFV-G, confirming that the MGF110-5L-6L gene is not involved in producing disease in swine. Sera from animals inoculated with an efficacious vaccine candidate, ASFV-G-ΔMGF, strongly recognized the protein encoded by the MGF110-5L-6L gene as a potential target for the development of an antigenic marker differentiation of infected from vaccinated animals (DIVA) vaccine. To test this hypothesis, the MGF110-5L-6L gene was deleted from the highly efficacious ASFV vaccine candidate ASFV-G-ΔI177L, generating the recombinant ASFV-G-ΔI177L/ΔMGF110-5L-6L. Animals inoculated with ASFV-G-ΔI177L/ΔMGF110-5L-6L developed an ASFV-specific antibody response detected by enzyme-linked immunosorbent assay (ELISA). The sera strongly recognized ASFV p30 expressed in eukaryotic cells but did not recognize ASFV MGF110-5L-6L protein, demonstrating that deletion of the MGF110-5L-6L gene can enable DIVA capabilities in preexisting vaccine candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.